Mind Medicine (mindmed) INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Commodore Capital LP and its affiliates have reported a beneficial ownership of 1.8% of Definium Therapeutics, Inc. common shares, acquiring them through a combination of direct holdings and pre-funded warrants.
Driehaus Capital Management LLC has amended its Schedule 13G filing to report a decrease in its beneficial ownership of Definium Therapeutics, Inc. common stock to 5.36% as of June 30, 2026.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported beneficial ownership of 3,000,000 shares, representing 3.01% of Definium Therapeutics, Inc. common stock as of March 31, 2026.
Driehaus Capital Management LLC reports a 6.64% beneficial ownership stake in Definium Therapeutics, Inc., holding over 6.5 million shares.
Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a 5.08% beneficial ownership stake in Mind Medicine (MindMed) Inc. for investment purposes.
Deep Track Capital, LP and affiliates reported a 5.54% beneficial ownership stake in Definium Therapeutics, Inc. as of December 31, 2025.
Deep Track Capital and its affiliates have reported a 6.87% beneficial ownership stake in Mind Medicine (MindMed) Inc., including 4 million pre-funded warrants.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 8.19% in Mind Medicine (MindMed) Inc., totaling 6,500,000 common shares.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.3% of Mind Medicine (MindMed) Inc.'s common stock as of December 31, 2024.